Kenneth Galbraith, Zymeworks CEO

Zymeworks shows pos­i­tive — yet ear­ly — piv­otal da­ta in bile duct can­cers, plans ac­cel­er­at­ed ap­proval run

Zymeworks is show­ing off some new topline da­ta on its HER2 bis­pe­cif­ic an­ti­body — af­ter show­cas­ing a pos­i­tive da­ta turnout at AS­CO ear­li­er in 2022. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.